171 related articles for article (PubMed ID: 27443291)
1. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.
Gkotzamanidou M; Terpos E; Bamia C; Munshi NC; Dimopoulos MA; Souliotis VL
Blood; 2016 Sep; 128(9):1214-25. PubMed ID: 27443291
[TBL] [Abstract][Full Text] [Related]
2. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
[TBL] [Abstract][Full Text] [Related]
3. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.
Gkotzamanidou M; Sfikakis PP; Kyrtopoulos SA; Bamia C; Dimopoulos MA; Souliotis VL
Br J Cancer; 2014 Sep; 111(7):1293-304. PubMed ID: 25051404
[TBL] [Abstract][Full Text] [Related]
4. The Combination of Panobinostat and Melphalan for the Treatment of Patients with Multiple Myeloma.
Gkotzamanidou M; Terpos E; Dimopoulos MA; Souliotis VL
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555311
[TBL] [Abstract][Full Text] [Related]
5. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
6. PARP Inhibition Synergizes with Melphalan but Does not Reverse Resistance Completely.
Patel PR; Senyuk V; Sweiss K; Calip GS; Pan D; Rodriguez N; Oh A; Mahmud N; Rondelli D
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1273-1279. PubMed ID: 32194286
[TBL] [Abstract][Full Text] [Related]
7. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells.
Chen Q; Van der Sluis PC; Boulware D; Hazlehurst LA; Dalton WS
Blood; 2005 Jul; 106(2):698-705. PubMed ID: 15802532
[TBL] [Abstract][Full Text] [Related]
8. Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Spanswick VJ; Lowe HL; Newton C; Bingham JP; Bagnobianchi A; Kiakos K; Craddock C; Ledermann JA; Hochhauser D; Hartley JA
BMC Cancer; 2012 Sep; 12():436. PubMed ID: 23020514
[TBL] [Abstract][Full Text] [Related]
9. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.
Spanswick VJ; Craddock C; Sekhar M; Mahendra P; Shankaranarayana P; Hughes RG; Hochhauser D; Hartley JA
Blood; 2002 Jul; 100(1):224-9. PubMed ID: 12070031
[TBL] [Abstract][Full Text] [Related]
10. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Mol Cell Biol; 2000 Nov; 20(21):7980-90. PubMed ID: 11027268
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 affects melphalan-induced DNA damage and repair in human multiple myeloma cells.
Efferth T; Fabry U; Osieka R
Anticancer Res; 2002; 22(1A):231-4. PubMed ID: 12017294
[TBL] [Abstract][Full Text] [Related]
12. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC
Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276
[TBL] [Abstract][Full Text] [Related]
13. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
14. Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey.
Ciftciler R; Goker H; Buyukasık Y; Aladag E; Saglam EA; Demiroglu H
Transfus Apher Sci; 2019 Jun; 58(3):313-317. PubMed ID: 30928228
[TBL] [Abstract][Full Text] [Related]
15. Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus.
Souliotis VL; Vougas K; Gorgoulis VG; Sfikakis PP
Arthritis Res Ther; 2016 Aug; 18(1):182. PubMed ID: 27492607
[TBL] [Abstract][Full Text] [Related]
16. Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability.
Herrero AB; San Miguel J; Gutierrez NC
PLoS One; 2015; 10(3):e0121581. PubMed ID: 25790254
[TBL] [Abstract][Full Text] [Related]
17. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
18. In vitro evidence for homologous recombinational repair in resistance to melphalan.
Wang ZM; Chen ZP; Xu ZY; Christodoulopoulos G; Bello V; Mohr G; Aloyz R; Panasci LC
J Natl Cancer Inst; 2001 Oct; 93(19):1473-8. PubMed ID: 11584063
[TBL] [Abstract][Full Text] [Related]
19. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
Pu Q; Bianchi P; Bezwoda WR
Anticancer Res; 2000; 20(4):2561-8. PubMed ID: 10953327
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients.
Thyagarajan B; Arora M; Guan W; Barcelo H; Jackson S; Kumar S; Gertz M
Leuk Res; 2013 Nov; 37(11):1527-31. PubMed ID: 24129343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
